Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to MDS With del5q, Refractory/Resistant/Intolerant to Prior Treatments, RBC-TD

Anemia Clinical Trial

— Phoenix  

Official title:

Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to Myelodysplastic Syndromes With del5q, Refractory/Resistant/Intolerant to Prior Treatments, Who Require Red Blood Cell Transfusions

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05924100
• Other study ID #: QOL-ONE Phoenix
• Status: Recruiting
• Phase: Phase 2
• Start date: November 3, 2022
• Est. completion date: November 3, 2028

Study information

• Verified date: June 2023
• Source: Associazione Qol-one
• Contact: Esther N Oliva, MD
• Phone: +393298699514
• Email: trials[@]qol-one.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Myelodysplastic syndromes, primarily affecting older adults, are a heterogeneous group of clonal disorders of hematopoietic stem cells characterized by ineffective hematopoiesis that manifest clinically as anemia, neutropenia, and/or thrombocytopenia of variable severity; these often result in RBC- transfusion dependent (TD) anemia, increased risk of infection, and/or hemorrhage, as well as a potential to progress to acute myeloid leukemia (AML).

Lenalidomide is approved for red blood cell transfusion-dependent (RBC TD) anemia due to low-risk myelodysplastic syndromes (MDS) with a chromosome 5q deletion (del5q) with or without additional cytogenetic abnormalities. About one third of patients are refractory/resistant/intolerant and will require further treatment options.

Luspatercept (ACE-536), an erythroid maturation agent, is a recombinant fusion protein consisting of a modified form of the extracellular domain (ECD) of the human activin receptor type IIB (ActRIIB) linked to the Fc portion of human immunoglobulin G1 (IgG1-Fc). Luspatercept acts on endogenous inhibitors of late-stage erythropoiesis (eg, growth differentiation factor 11, GDF11) to increase release of mature erythrocytes into circulation. Nonclinical data have demonstrated that luspatercept binds to negative regulators governing late-stage erythroid development to inhibit their action, thereby promoting the maturation of erythrocytes in the bone marrow.

Luspatercept is indicated for the treatment of adult patients with transfusion-dependent anaemia associated with beta-thalassaemia and due to very low, low and intermediate-risk MDS with ring sideroblasts, who had an unsatisfactory response to or are ineligible for erythropoietin-based-therapy. It is not indicated for other MDS subtypes. Unfortunately, patients with MDS with del5q refractory/resistant/intolerant to lenalidomide are excluded from clinical trials that evaluate novel treatments for the anemia of RBC TD lower risk MDS. Therefore, treatment of anemia in such patients is an unmet need.

QOL-ONE Phoenix is a Phase 2, multicenter, single arm, prospective study. The primary objective of the study is to evaluate the effect of luspatercept on RBC TI in subjects with MDS with del5q with IPSS-R very low, low, or intermediate risk and < 5% bone marrow blasts, resistant/refractory/intolerant to lenalidomide and who require RBC transfusions.

The study is divided into a Screening Period, a 2-year Treatment Period and a 3-year Follow-up Period.

Primary objective is to evaluate the effect of luspatercept on RBC TI (lack of transfusions for 8 consecutive weeks within the first 24 weeks) in subjects with MDS with del5q with IPSS-R very low, low, or intermediate risk and < 5% bone marrow blasts, resistant/refractory/intolerant to lenalidomide and RBC TD.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 22
• Est. completion date: November 3, 2028
• Est. primary completion date: April 3, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Subject must understand and voluntarily sign an ICF prior to any study-related assessments/procedures being conducted.

2. Documented diagnosis of MDS with del5q according to 2018 WHO classification

3. IPSS-R classification (Greenberg, 2012) of very low, low, or intermediate risk disease, and:

• < 5% blasts in bone marrow

• Peripheral blood WBC count <13,000/µL

4. Refractory or intolerant to, or ineligible for, prior ESA treatment

5. If previously treated with ESAs or granulocyte colony-stimulating factor (G-CSF), both agents must have been discontinued = 4 weeks prior to date of screening.

6. Refractory or intolerant to, or ineligible for, prior lenalidomide treatment, as defined by any one of the following:

• Refractory to prior lenalidomide treatment for at least 4 cycles; - documentation of non-response or response that is no longer maintained (HI-E)

• Intolerant to prior lenalidomide treatment - documentation of discontinuation of lenalidomide at any time after introduction due to intolerance or an adverse event

• lenalidomide ineligible -platelet counts below 50000/mmc or absolute neutrophil count below 500/mmc at the start of treatment

• lenalidomide must have been discontinued = 4 weeks prior to date of screening.

Requires RBC transfusions, as documented by the following criteria:

• average transfusion requirement of = 2 units/8 weeks of pRBCs confirmed for a minimum of 16 weeks immediately preceding enrolment.

• Hb levels at the time of or within 7 days prior to administration of a RBC transfusion must have been = 10.0 g/dL in order for the transfusion to be counted towards meeting eligibility criteria. RBC transfusions administered when Hb levels were > 10.0 g/dL and/or RBC transfusions administered for elective surgery will not qualify as a required transfusion for the purpose of meeting eligibility criteria.

• no consecutive 56-day period that was RBC transfusion-free during the 16 weeks immediately preceding screening

7. Eastern Cooperative Oncology Group (ECOG) score of 0, 1, or 2

8. Females of childbearing potential, defined as a sexually mature woman who: 1) has not undergone a hysterectomy or bilateral oophorectomy or 2) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (ie, has had menses at any time in the preceding 24 consecutive months), must:

• Have two negative pregnancy tests as verified by the Investigator prior to starting study therapy (unless the screening pregnancy test was done within 72 hours of C1D1). Refer to Section 6.1 for additional details. She must agree to ongoing pregnancy testing during the course of the study, and after the end of study treatment.

• If sexually active, agree to use, and be able to comply with, highly effective contraception without interruption, 5 weeks prior to starting investigational product, during the study therapy (including dose interruptions), and for 12 weeks after discontinuation of study therapy.

9. Male subjects must:

• Agree to use a condom, defined as a male latex condom or non latex condom not made out of natural (animal) membrane (for example, polyurethane), during sexual contact with a pregnant female or a female of childbearing potential while participating in the study, during dose interruptions and for at least 12 weeks following investigational product discontinuation, even if he has undergone a successful vasectomy.

10. Subject is willing and able to adhere to the study visit schedule and other protocol requirements.

Exclusion Criteria:

1. P53 mutation at screening

2. Prior therapy with disease modifying agents for underlying MDS disease (hypomethylating agents)

• subjects who previously received HMA may be enrolled at the investigator's discretion contingent that the subject received no more than 1 dose of HMA). The last dose must be = 5 weeks from the date of screening.

3. Previously treated with either luspatercept (ACE-536) or sotatercept (ACE-011)

4. Secondary MDS, ie, MDS that is known to have arisen as the result of chemical injury or treatment with chemotherapy and/or radiation for other diseases. 5 Known clinically significant anemia due to iron, vitamin B12, or folate deficiencies, or autoimmune or hereditary hemolytic anemia, or gastrointestinal bleeding

6. Prior allogeneic or autologous stem cell transplant 7. Known history of diagnosis of AML

8. Use of any of the following within 5 weeks prior to study entry:

• anticancer cytotoxic chemotherapeutic agent or treatment

• corticosteroid, except for subjects on a stable or decreasing dose for = 1 week prior to study entry for medical conditions other than MDS

• iron-chelating agents, except for subjects on a stable or decreasing dose for at least 8 weeks prior to screening

• other RBC hematopoietic growth factors

• investigational drug or device, or approved therapy for investigational use. If the half- life of the previous investigational product is known, use within 5 times the half- life prior to screening or within 5 weeks, whichever is longer is excluded. 9. Uncontrolled hypertension, defined as repeated elevations of diastolic blood pressure (DBP) = 100 mmHg despite adequate treatment. 10. Estimated glomerular filtration rate (eGFR) or creatinine clearance < 40 mL/min.

11. Serum aspartate aminotransferase/serum glutamic oxaloacetic transaminase or alanine aminotransferase/serum glutamic pyruvic transaminase = 3.0 x upper limit of normal (ULN) 12. Total bilirubin = 2.0 x ULN.

• higher levels are acceptable if these can be attributed to active red blood cell precursor destruction within the bone marrow (ie, ineffective erythropoiesis) or in the presence of known history of Gilbert Syndrome.

• subjects are excluded if there is evidence of autoimmune hemolytic anemia 13. Prior history of malignancies, other than MDS, unless the subject has been free of the disease (including completion of any active or adjuvant treatment for prior malignancy) for = 5 years. However, subjects with the following history/concurrent conditions are allowed:

• Basal or squamous cell carcinoma of the skin

• Carcinoma in situ of the cervix

• Carcinoma in situ of the breast

• Incidental histologic finding of prostate cancer (T1a or T1b using the tumor, nodes, metastasis [TNM] clinical staging system)

Related Conditions & MeSH terms

• Anemia
• Myelodysplastic Syndromes
• Preleukemia
• Syndrome
• Transfusion-dependent Anemia

Intervention

Drug:
• Luspatercept Injection [Reblozyl]
Eligible subjects will receive luspatercept (ACE-536): starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (21 days; Q3W). Dose levels can be increased in a stepwise manner beyond the starting dose to 1.33 mg/kg, and up to a maximum of 1.75 mg/kg (with a maximum total dose of 168 mg). All subjects who have received at least one dose of luspatercept should undergo follow-up evaluations after day 169 with Assessment visits every 24 weeks (168 days) up to 2 years to evaluate evidence of clinical benefit.

Locations

Country	Name	City	State
Italy	A.O. SS. Antonio e Biagio e Cesare Arrigo Ospedale Civile	Alessandria
Italy	A.O.U. Ospedali Riuniti	Ancona
Italy	A.O. S. Giuseppe Moscati	Avellino
Italy	Ospedale degli Infermi	Biella
Italy	A.O.U. G. Rodolico San Marco	Catania
Italy	ARNAS Garibaldi, PO Nesima	Catania
Italy	ASL TO 4 - Ospedale Chivasso	Chivasso
Italy	Azienda Ospedaliera Annunziata	Cosenza
Italy	A.O.U. Careggi	Firenze
Italy	A.O.U. Federico II	Napoli
Italy	A.O.U. Maggiore della Carità	Novara
Italy	A.O.U. Policlinico Paolo Giaccone	Palermo
Italy	Ospedale Civile Spirito Santo	Pescara
Italy	Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli	Reggio Calabria
Italy	IRCCS di Reggio Emilia	Reggio Emilia
Italy	Ospedale S. Eugenio	Roma
Italy	Policlinico Tor Vergata	Roma
Italy	Policlinico Umberto I	Roma
Italy	A.O.U. San Giovanni di Dio e Ruggì D'Aragona	Salerno
Italy	Casa Sollievo della Sofferenza IRCCS	San Giovanni Rotondo
Italy	AO Santa Maria di Terni	Terni
Italy	A.O. Città della Salute e della Scienza	Torino
Italy	ASU Giuliano Isontina	Trieste

Sponsors (1)

Lead Sponsor	Collaborator
Associazione Qol-one

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	RBC Transfusion Independence	Proportion of subjects who are RBC TI for 8 weeks over the first 24 weeks from trial entry	24 WEEKS
Secondary	Safety and tolerability of Luspatercept measured as frequency and severity of adverse events occurred and assessed by CTCAE v. 5.0	Type, frequency, severity of AEs. The adverse events occurring in the subjects enrolled in the study will be evaluated according to CTCAE v5.0 Furthermore, the relationship between adverse events and treatment with luspatercept will be evaluated	5 years
Secondary	RBC-TI in long term	Proportion of subjects who are RBC TI for 8 weeks over the first 48 weeks from trial entry and over the 30 months	5 years
Secondary	Duration of RBC-TI	Maximum duration of RBC transfusion independence for subjects who achieve RBC TI = 8 weeks	2 years
Secondary	Reduction in RBC transfusions	Mean change in total pRBC units transfused over a rolling 8-week period and proportion achievieng HI-E (reduction in = 4 units in the preceding 8 weeks in those with baseline transfusion burden of =8 units in 8 preceding weeks)	24 weeks
Secondary	Increase in hemoglobin	Mean change in hb levels from baseline and proportion achieving HI-E (gain in Hb =1.5 g/dL)	2 years
Secondary	Change in quality of life scores with QOL-E questionnaire	Scores of QOL-E questionnaire from baseline and proportion achieving meaningful clinical important difference)	2 years
Secondary	Change in quality of life scores with HM-PRO questionnaire	Scores of HM-PRO questionnaire from baseline and proportion achieving meaningful clinical important difference)	2 years
Secondary	Change in Serum Ferritin	Mean change of serum ferritin from baseline	2 years
Secondary	Change in iron chelation therapy use	Mean change of iron chelation therapy use from baseline	2 years
Secondary	Time to RBC TI	Time to achieving first RBC TI = 8 weeks in the first 24 weeks	2 years